AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16471172 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 39
Study 16471172 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 39
Study 12742806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting triglyceride levels
Number of subjects: 2809
Study 12742806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting triglyceride levels
Number of subjects: 2809
Study 10505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.05‐0.8 mg orally, given as single or multiple once‐daily doses
Number of subjects: 0
Study 10505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin with a high‐fat meal
Number of subjects: 0
Study 10505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin administered at different times (morning, evening meal, bedtime)
Number of subjects: 0
Study 10505300 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed tablet strengths and drug formulations from different sources
Number of subjects: 0
Study 8605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 0.1 mg/kg (n = 3)
Number of subjects: 9
Study 8605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 0.33 mg/kg (n = 3)
Number of subjects: 9
Study 8605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787 at 1.0 mg/kg (n = 3)
Number of subjects: 9
Study 8605793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of murine monoclonal antibody to E‐selectin, CY1787
Number of subjects: 9
Study 1709039 — intervention group
Group type: EXPERIMENTAL
Intervention: Spantide (substance P antagonist)
Number of subjects: 0
Study 1709039 — intervention group
Group type: COMPARATOR
Intervention: Control (no substance P antagonist)
Number of subjects: 0
Study 31711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including three antenatal counselling sessions on diet and physical activity and one postpartum session
Number of subjects: 2101
Study 31711430 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care
Number of subjects: 2101
Study 31711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2101
Study 29590461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 284
Study 29590461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 27688117 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 40
Study 27688117 — intervention group
Group type: COMPARATOR
Intervention: Electro cautery (EC)
Number of subjects: 40
Study 25350851 — intervention group
Group type: COMPARATOR
Intervention: RV144 vaccine
Number of subjects: 110
Study 22594098 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (20 sessions for approximately one and a half months)
Number of subjects: 87
Study 22594098 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group 1)
Number of subjects: 87
Study 22594098 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group 2)
Number of subjects: 87
Study 19672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 225 mcg/l lutein
Number of subjects: 40
Study 19672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 120 mcg/l lutein
Number of subjects: 40
Study 19672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 45 mcg/l lutein
Number of subjects: 40
Study 19672550 — intervention group
Group type: COMPARATOR
Intervention: Unfortified formula (20 mcg/l lutein)
Number of subjects: 40
Study 19672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 40
Study 19672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 40
Study 17917517 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 44
Study 17917517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16193896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 800 mg/m2 plus methylprednisolone 1 g IV (CY/MP)
Number of subjects: 59
Study 16193896 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone once a month for six months (MP)
Number of subjects: 59
Study 11831539 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of amifostine (500 mg)
Number of subjects: 12
Study 11831539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of amifostine (500 mg)
Number of subjects: 12
Study 11831539 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of amifostine (200 mg/m2)
Number of subjects: 12
Study 10427933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iodized oil (OIO)
Number of subjects: 617
Study 10427933 — intervention group
Group type: COMPARATOR
Intervention: Placebo (poppy-seed oil)
Number of subjects: 617
Study 7553231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of subcutaneously injected recombinant IFN‐alpha 2b three times per week for 6 months
Number of subjects: 50
Study 7553231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 50
Study 7553231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of subcutaneously injected recombinant IFN‐alpha 2b
Number of subjects: 50
Study 7553231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretreatment levels of HCV RNA
Number of subjects: 50
Study 2142699 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine, 100 mg/kg/day
Number of subjects: 65
Study 2142699 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine, 2.5 mg/kg/day
Number of subjects: 65
Study 2142699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7024155 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 1000 kcal diet with diethylpropion permitted
Number of subjects: 0
Study 7024155 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric partial meal replacement with protein powder, and diethylpropion permitted
Number of subjects: 0
Study 7024155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal satiation with protein powder
Number of subjects: 0
Study 31931928 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous lag screw internal fixation
Number of subjects: 130
Study 31931928 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction plate
Number of subjects: 130
Study 30303746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025%
Number of subjects: 81
Study 30303746 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen 0.05%
Number of subjects: 81
Study 28085735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 12
Study 28085735 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 12
Study 26424589 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal microbiome modulator (GIMM)
Number of subjects: 30
Study 26424589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24844352 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral urotherapy combined with pelvic floor muscle (PFM) exercises
Number of subjects: 60
Study 24844352 — intervention group
Group type: COMPARATOR
Intervention: Behavioral urotherapy
Number of subjects: 60
Study 22946066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-call intervention delivered to all babies at aged four weeks
Number of subjects: 0
Study 22946066 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19875843 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes of immobilisation after intrauterine insemination
Number of subjects: 391
Study 19875843 — intervention group
Group type: COMPARATOR
Intervention: Immediate mobilisation after insemination (control)
Number of subjects: 391
Study 16878429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg t.i.d. for 16 weeks
Number of subjects: 40
Study 16878429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12681885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monophasic oral contraceptives
Number of subjects: 12
Study 12681885 — intervention group
Group type: COMPARATOR
Intervention: Control group (women not using oral contraceptives)
Number of subjects: 12
Study 10823361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% BID
Number of subjects: 40
Study 10823361 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% QD
Number of subjects: 40
Study 10823361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine with concomitant pilocarpine
Number of subjects: 40
Study 10823361 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost with concomitant pilocarpine
Number of subjects: 40
Study 10823361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine with concomitant dorzolamide
Number of subjects: 40
Study 10823361 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost with concomitant dorzolamide
Number of subjects: 40
Study 8888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5 mg
Number of subjects: 214
Study 8888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 214
Study 8888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 214
Study 8888663 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 75 mg
Number of subjects: 214
Study 8888663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 2001757 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo transfer
Number of subjects: 94
Study 2001757 — intervention group
Group type: COMPARATOR
Intervention: Traditional blind embryo transfer technique
Number of subjects: 94
Study 6872169 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 10
Study 6872169 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg verapamil
Number of subjects: 10
Study 6872169 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 to 30 mg)
Number of subjects: 10
Study 6872169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31076421 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolffia globosa Mankai shake
Number of subjects: 20
Study 28645983 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release Mg hydroxide 30 mmol/day
Number of subjects: 250
Study 28645983 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 250
Study 25890643 — intervention group
Group type: COMPARATOR
Intervention: Pomaglumetad 40 mg BID
Number of subjects: 206
Study 25890643 — intervention group
Group type: COMPARATOR
Intervention: Pomaglumetad 80 mg BID
Number of subjects: 206
Study 25890643 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 2 mg BID
Number of subjects: 206
Study 23146549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 400
Study 23146549 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 400
Study 21383219 — intervention group
Group type: EXPERIMENTAL
Intervention: SCID interview
Number of subjects: 506
Study 21383219 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 survey
Number of subjects: 506
Study 21383219 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 score elevations (≥15)
Number of subjects: 506
Study 21383219 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 scores
Number of subjects: 506
Study 18645513 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Sex Skills Building (SSB) groups, five 90-minute sessions focusing on problem solving and skills rehearsal.
Number of subjects: 515
Study 18645513 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV/STD Education (HE), one 60-minute session covering disease, testing, treatment, and prevention information.
Number of subjects: 515
Study 16615668 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina extract (250 mg) plus zinc (2 mg) twice daily for 16 weeks
Number of subjects: 41
Study 16615668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16615668 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina extract plus zinc
Number of subjects: 41
Study 14718876 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc curing light (Apollo 95E)
Number of subjects: 45
Study 14718876 — intervention group
Group type: COMPARATOR
Intervention: Conventional curing unit (Ortholux XL 3000)
Number of subjects: 45
Study 14718876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 45
Study 11167866 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 583
Study 11167866 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 583
Study 9559082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract on etched enamel
Number of subjects: 36
Study 9559082 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass on unetched enamel
Number of subjects: 36
Study 9559082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract and Compoglass on dentin
Number of subjects: 36
Study 9559082 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of Dyract and Compoglass
Number of subjects: 36
Study 7837405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.5 mg administered immediately after induction of spinal anesthesia (i.v. group)
Number of subjects: 40
Study 7837405 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular atropine 0.5 mg administered 30 min before induction of spinal anesthesia (i.m. group)
Number of subjects: 40
Study 2904776 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg once daily
Number of subjects: 65
Study 2904776 — intervention group
Group type: EXPERIMENTAL
Intervention: astemizole 10 mg once daily
Number of subjects: 65
Study 2904776 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 29741594 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (Preexposure Prophylaxis)
Number of subjects: 4064
Study 27009063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy
Number of subjects: 73
Study 27009063 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 73
Study 27009063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 73
Study 24622724 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantisal collection device
Number of subjects: 0
Study 24622724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-Eze collection device
Number of subjects: 0
Study 24622724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-tandem mass spectrometry method
Number of subjects: 0
Study 23398305 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental meta-intervention
Number of subjects: 41
Study 23398305 — intervention group
Group type: COMPARATOR
Intervention: Control meta-intervention
Number of subjects: 41
Study 20692186 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 72
Study 20692186 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2.0%
Number of subjects: 72
Study 20692186 — intervention group
Group type: EXPERIMENTAL
Intervention: No pretreatment
Number of subjects: 72
Study 20692186 — intervention group
Group type: COMPARATOR
Intervention: Storage time
Number of subjects: 72
Study 18423151 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 112
Study 16767058 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplastic neutral wrist splint for night-only wear
Number of subjects: 50
Study 14622709 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and capsaicin
Number of subjects: 20
Study 14622709 — intervention group
Group type: COMPARATOR
Intervention: Heat alone
Number of subjects: 20
Study 14622709 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin alone
Number of subjects: 20
Study 14622709 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat/capsaicin
Number of subjects: 20
Study 14622709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rekindling
Number of subjects: 20
Study 10828633 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum-based formulation delivered by the novel diaper
Number of subjects: 391
Study 10828633 — intervention group
Group type: COMPARATOR
Intervention: Control diaper (identical to test product without petrolatum formulation)
Number of subjects: 391
Study 9380327 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal closure
Number of subjects: 120
Study 9380327 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal nonclosure
Number of subjects: 120
Study 8102554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (V) 0.01 mg kg-1 BW followed by 0.04 mg kg-1 BW
Number of subjects: 0
Study 8102554 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (A) 0.05 mg kg-1 BW followed by 0.2 mg kg-1 BW
Number of subjects: 0
Study 8102554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of V and A in the 'priming'-technique
Number of subjects: 0
Study 2880114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol implants
Number of subjects: 0
Study 2880114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol/testosterone implants
Number of subjects: 0
Study 2880114 — intervention group
Group type: COMPARATOR
Intervention: Placebo implants
Number of subjects: 0
Study 29096997 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior LPI (n = 285)
Number of subjects: 559
Study 29096997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal/temporal LPI (n = 274)
Number of subjects: 559
Study 29096997 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Superior LPI and Nasal/temporal LPI)
Number of subjects: 559
Study 26653541 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 0
Study 26653541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 24433865 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacytarabine
Number of subjects: 43
Study 22407339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Physical activity intervention for 5 months
Number of subjects: 150
Study 22407339 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 150
Study 19051099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride tablets (2 g) thrice daily for 4 days
Number of subjects: 22
Study 19051099 — intervention group
Group type: COMPARATOR
Intervention: Standardized fluid intake and diet
Number of subjects: 22
Study 17964349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (0.025 microg/kg per min for 3 days)
Number of subjects: 1216
Study 17964349 — intervention group
Group type: COMPARATOR
Intervention: Placebo for atrial natriuretic peptide
Number of subjects: 1216
Study 17964349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.067 mg/kg as a bolus, followed by 1.67 microg/kg per min as a 24-h continuous infusion)
Number of subjects: 1216
Study 17964349 — intervention group
Group type: COMPARATOR
Intervention: Placebo for nicorandil
Number of subjects: 1216
Study 14694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of epidermal Langerhans cells
Number of subjects: 0
Study 14694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of epidermal IL-4
Number of subjects: 0
Study 14694529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cells, T-lymphocytes, and macrophages
Number of subjects: 0
Study 11244200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 11244200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 0
Study 11244200 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 11244200 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin, low‐molecular‐weight heparin, heparinoids
Number of subjects: 0
Study 11244200 — intervention group
Group type: COMPARATOR
Intervention: Fraxaripine
Number of subjects: 0
Study 11244200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9794982 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-diphtheria-tetanus immunization
Number of subjects: 100
Study 9794982 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 100
Study 9794982 — intervention group
Group type: EXPERIMENTAL
Intervention: VAERS-based studies
Number of subjects: 100
Study 9794982 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive study of HHE
Number of subjects: 100
Study 9794982 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control study of factors affecting risk of HHE
Number of subjects: 100
Study 8004592 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mass screening programs with mammography for women aged 50-69
Number of subjects: 0
Study 8004592 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mass screening programs with mammography for women aged 40-49
Number of subjects: 0
Study 8004592 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual examinations with mammography and clinical breast examination (HIP and Canadian National Breast Screening Study)
Number of subjects: 0
Study 8004592 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer intervals between examinations with mammography alone (most other trials)
Number of subjects: 0
Study 2785684 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 75
Study 2785684 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 75
Study 2785684 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 75
Study 132330 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose therapy with phenytoin (4 doses of 4.4 to 6.3 mg/kg/dose given 8-hourly and then 6 mg/kg/day)
Number of subjects: 13